Venture Management Co. V, L... Net Worth

The estimated Net Worth of Venture Management Co. V, L... is at least $1.96 ezer dollars as of 5 May 2020. Venture L owns over 62,500 units of Lyra Therapeutics stock worth over $1,964 and over the last 5 years Venture sold LYRA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture L LYRA stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Lyra Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 62,500 units of LYRA stock worth $1,000,000 on 5 May 2020.

The largest trade Venture's ever made was buying 62,500 units of Lyra Therapeutics stock on 5 May 2020 worth over $1,000,000. On average, Venture trades about 62,500 units every 0 days since 2020. As of 5 May 2020 Venture still owns at least 7,274 units of Lyra Therapeutics stock.

You can see the complete history of Venture L stock trades at the bottom of the page.

Insiders trading at Lyra Therapeutics

Over the last 5 years, insiders at Lyra Therapeutics have traded over $0 worth of Lyra Therapeutics stock and bought 19,620,470 units worth $85,899,322 . The most active insiders traders include Advisors Llcperceptive Life..., Edward T Anderson és Gp, Llcdamore Richard Anort.... On average, Lyra Therapeutics executives and independent directors trade stock every 76 days with the average trade being worth of $311,619. The most recent stock trade was executed by Harlan Waksal on 10 November 2023, trading 25,000 units of LYRA stock currently worth $74,000.

What does Lyra Therapeutics do?

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Complete history of Venture L stock trades at Lyra Therapeutics

Lyra Therapeutics executives and stock owners

Lyra Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Maria Palasis Ph.D.,
  CEO, Pres & Director
• R. Donald Elsey MBA,
  Advisor
• Dr. Robert Richard Ph.D.,
  Sr. VP of R&D
• Pamela E. Nelson,
  Sr. VP of Regulatory Affairs
• Vineeta Belanger Ph.D.,
  Sr. VP of Clinical Affairs
• Corinne Noyes,
  Sr. VP of Commercial Strategy & Market Devel.
• Ray Knox,
  VP of Operations
• Jason Cavalier,
  Chief Financial Officer
• Dr. Carmichael S. Roberts Jr., Ph.D.,
  Co-Founder
• Dr. Harlan W. Waksal M.D.,
  Exec. Chairman
• Maria Palasis,
  President & CEO
• Carmichael Roberts,
  10% owner
• Robert Langer,
  Director
• Advisors Llcperceptive Life...,
  
• George M Whitesides,
  Director
• Venture Management Co. V, L...,
  
• R Don Elsey,
  CFO, Treasurer & Secretary
• Gp, Llcdamore Richard Anort...,
  
• Private Equity Gp I, Llc So...,
  
• Laura Edgerly Pflug,
  See Remarks
• Corinne Noyes,
  See Remarks
• Michael Seth Altman,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcedelman Joseph ...,
  
• Jason Cavalier,
  Chief Financial Officer
• Robert E. Richard,
  SVP, Technical Operations
• Pamela E. Nelson,
  SVP, Regulatory Affairs
• Harlan Waksal,
  Executive Chair
• Richard Nieman,
  Chief Medical Officer
• John E Bishop,
  Chief Technology Officer
• C Ann Merrifield,
  
• James R Tobin,
  
• Nancy Lynn Md Snyderman,
  
• Konstantin Poukalov,
  
• Edward T Anderson,
  
• W Bradford Smith,